Amlodipine – facts and myths Review article
Article Sidebar
Published:
Jul 10, 2018
Keywords:
arterial hypertension, cardiovascular diseases, dihydropyridine calcium antagonists, amlodipine
Main Article Content
Abstract
Amlodipine – the 3rd generation dihydropyridine calcium antagonist is one of the most commonly used antihypertensive drugs. The exceptionally strong and still stable position of amlodipine in modern pharmacotherapy of cardiovascular diseases results from the fact that amlodipine is best studied in all drugs in this group. The paper presents the current state of knowledge on the wide possibilities of using this drug in the population of patients with hypertension and co-morbidities.
Downloads
Download data is not yet available.
Article Details
How to Cite
Grabysa , R. (2018). Amlodipine – facts and myths. Cardiology in Practice, 12(2), 18-22. Retrieved from https://journalsmededu.pl/index.php/kwp/article/view/1215
Issue
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Toyo-oka T., Naylor W.G.: Third generation calcium entry blockers. Blood Press. 1996; 5(4): 206-208.
2. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288(23): 2981-2997.
3. Dahlöf B., Sever P.S., Poulter N.R. et al.; ASCOT Investigators: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.
4. Julius S., Kjeldsen S.E., Weber M. et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-2031.
5. Jamerson K., Weber M.A., Bakris G.L. et al.; for the ACCOMPLISH Trial Investigators: Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients. N. Engl. J. Med. 2008; 359: 2417-2428.
6. Barylski M.: Dwanaście powodów, dla których warto stosować amlodipinę. Medycyna Faktów 2014; 4(25): 41-47.
7. Pitt B., Byington R.P., Furberg C.D. et al.; PREVENT Investigators: Effect of amlodipine on progression of atherosclerosis and the occurence of clinical events. Circulation 2000; 102: 1503-1510.
8. Nissen S.E., Tuzcu E.M., Libby P. et al.: Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292(18): 2217-2225.
9. Widecka K.: Czy terapia nadciśnienia tętniczego może zmniejszyć ryzyko zaburzeń funkcji poznawczych i otępienia. Arterial Hypertens. 2017; 2: 61-68.
10. Feldman L., Vinker S., Efrati S. et al.: Amlodipine treatment of hypertension associates with decreased dementia risk. Clin. Exp. Hypertens. 2016; 38(6): 545-549.
11. Montalescot G., Sechtem U., Achenbach S. et al.: Wytyczne ESC dotyczące postępowania w stabilnej chorobie wieńcowej w 2013 roku. Kardiol. Pol. 2013; 71(supl. X): 243-318.
12. Deanfield J.E., Detry J.M., Lichtlen P.R. et al.: Amlodipine reduces transient myocardial ischaemia in patients with coronary artery disease: double-blind Cicadian Anti-Ischaemia Program in Europe (CAPE Trial). J. Am. Coll. Cardiol. 1994; 24(6): 1460-1467.
13. Januszewicz A., Więcek A., Nieszporek T. et al. (red.): Nadciśnienie tętnicze pierwotne i wtórne w pytaniach i odpowiedziach. Medycyna Praktyczna, Kraków 2016: 169-170.
14. Pavličević I., Kuzmanić M., Rumboldt M. et al.: Interaction between antihypertensives and NSAIDS in primary care: a controlled trial. Can. J. Pharmacol. 2008; 3: e372-e382.
15. Romero J.C., Ruilope L.M., Bontley M.D. et al.: Comparison of the effects of calcium antagonist and converting enzyme inhibitor on renal function under normal and hypertensive conditions. Am. J. Cardiol. 1988; 62: 59G-68G.
16. Messerli F.H., Nol G., Lindholm L.H. et al.: The role of dihydropyridine calcium channel blockers in the treatment of hypertension and cardiovascular disease – an update. Eur. Cardiovasc. Dis. 2006; 2(1): 1-6.
17. Packer M., O’Connor C.M., Ghali J.K. et al.: Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N. Engl. J. Med. 1996; 335: 1107-1114.
18. Ponikowski P., Voors A.A., Anker S.D. et al.: Wytyczne ESC dotyczące diagnostyki i leczenia ostrej i przewlekłej niewydolności serca w 2016 roku. Kardiol. Pol. 2016; 74(10): 1037-1147.
19. Tykarski A., Narkiewicz K., Gaciong Z. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze w Praktyce 2015; 1: 1-70.
2. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288(23): 2981-2997.
3. Dahlöf B., Sever P.S., Poulter N.R. et al.; ASCOT Investigators: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.
4. Julius S., Kjeldsen S.E., Weber M. et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-2031.
5. Jamerson K., Weber M.A., Bakris G.L. et al.; for the ACCOMPLISH Trial Investigators: Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients. N. Engl. J. Med. 2008; 359: 2417-2428.
6. Barylski M.: Dwanaście powodów, dla których warto stosować amlodipinę. Medycyna Faktów 2014; 4(25): 41-47.
7. Pitt B., Byington R.P., Furberg C.D. et al.; PREVENT Investigators: Effect of amlodipine on progression of atherosclerosis and the occurence of clinical events. Circulation 2000; 102: 1503-1510.
8. Nissen S.E., Tuzcu E.M., Libby P. et al.: Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292(18): 2217-2225.
9. Widecka K.: Czy terapia nadciśnienia tętniczego może zmniejszyć ryzyko zaburzeń funkcji poznawczych i otępienia. Arterial Hypertens. 2017; 2: 61-68.
10. Feldman L., Vinker S., Efrati S. et al.: Amlodipine treatment of hypertension associates with decreased dementia risk. Clin. Exp. Hypertens. 2016; 38(6): 545-549.
11. Montalescot G., Sechtem U., Achenbach S. et al.: Wytyczne ESC dotyczące postępowania w stabilnej chorobie wieńcowej w 2013 roku. Kardiol. Pol. 2013; 71(supl. X): 243-318.
12. Deanfield J.E., Detry J.M., Lichtlen P.R. et al.: Amlodipine reduces transient myocardial ischaemia in patients with coronary artery disease: double-blind Cicadian Anti-Ischaemia Program in Europe (CAPE Trial). J. Am. Coll. Cardiol. 1994; 24(6): 1460-1467.
13. Januszewicz A., Więcek A., Nieszporek T. et al. (red.): Nadciśnienie tętnicze pierwotne i wtórne w pytaniach i odpowiedziach. Medycyna Praktyczna, Kraków 2016: 169-170.
14. Pavličević I., Kuzmanić M., Rumboldt M. et al.: Interaction between antihypertensives and NSAIDS in primary care: a controlled trial. Can. J. Pharmacol. 2008; 3: e372-e382.
15. Romero J.C., Ruilope L.M., Bontley M.D. et al.: Comparison of the effects of calcium antagonist and converting enzyme inhibitor on renal function under normal and hypertensive conditions. Am. J. Cardiol. 1988; 62: 59G-68G.
16. Messerli F.H., Nol G., Lindholm L.H. et al.: The role of dihydropyridine calcium channel blockers in the treatment of hypertension and cardiovascular disease – an update. Eur. Cardiovasc. Dis. 2006; 2(1): 1-6.
17. Packer M., O’Connor C.M., Ghali J.K. et al.: Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N. Engl. J. Med. 1996; 335: 1107-1114.
18. Ponikowski P., Voors A.A., Anker S.D. et al.: Wytyczne ESC dotyczące diagnostyki i leczenia ostrej i przewlekłej niewydolności serca w 2016 roku. Kardiol. Pol. 2016; 74(10): 1037-1147.
19. Tykarski A., Narkiewicz K., Gaciong Z. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze w Praktyce 2015; 1: 1-70.